| scholarly article | Q13442814 |
| P2093 | author name string | Jesse A Green | |
| Richard P Macdermott | |||
| P2860 | cites work | Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee | Q22242348 |
| Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
| Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 | ||
| Oral fluticasone propionate in active distal ulcerative colitis | Q34395369 | ||
| IIeal Pouch-Anal Anastomoses Complications and Function in 1005 Patients | Q34720950 | ||
| Guidelines for the management of inflammatory bowel disease in adults | Q35790559 | ||
| Randomised controlled trial of azathioprine withdrawal in ulcerative colitis | Q35822294 | ||
| Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety | Q35881304 | ||
| Methods to avoid infections in patients with inflammatory bowel disease | Q36171733 | ||
| Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease | Q36209752 | ||
| Optimizing therapy in patients with pancolitis | Q36270395 | ||
| Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement | Q36609204 | ||
| Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials | Q36609208 | ||
| A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis | Q39453095 | ||
| A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. | Q40988108 | ||
| Intravenous cyclosporin in ulcerative colitis: a five-year experience | Q41671378 | ||
| Cyclosporin for refractory ulcerative colitis | Q41858524 | ||
| Ileal pouch-anal anastomosis for chronic ulcerative colitis. Long-term results | Q43316632 | ||
| J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients | Q43333449 | ||
| Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis | Q43679139 | ||
| Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis | Q44255869 | ||
| Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 | ||
| Serial biopsy in ulcerative colitis | Q49163705 | ||
| Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. | Q54007642 | ||
| The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. | Q54323706 | ||
| Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. | Q55266577 | ||
| Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man | Q57265461 | ||
| 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity | Q69770535 | ||
| Intensive intravenous treatment of ulcerative colitis | Q69964499 | ||
| Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial | Q70171030 | ||
| The problem with pouchitis | Q70634997 | ||
| The long-term outcome of ulcerative colitis treated with 6-mercaptopurine | Q71500638 | ||
| Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis | Q71841215 | ||
| Cyclosporin for severe ulcerative colitis: a user's guide | Q73747657 | ||
| Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis | Q73978420 | ||
| Infliximab for refractory ulcerative colitis | Q74400737 | ||
| Cytomegalovirus infection in patients with inflammatory bowel disease | Q77319026 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 64-69 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Gastroenterology & hepatology | Q26842161 |
| P1476 | title | Refractory ulcerative colitis treatment | |
| P478 | volume | 3 |
| Q92619703 | Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome |
| Q36157372 | Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice |
| Q42054198 | Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures. |
Search more.